Biofreedom Prospective Multicenter Observational Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

194 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-05

Study Completion Date

2020-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

LEADERS-FREE trial demonstrated the safety and efficacy of polymer-free drug-coated stent (Biofreedom, Biosensors International Technologies, Singapore) in patients with high bleeding risk. But, there are limited clinical evidences for extending these findings to generalized patients who are eligible to PCI. Therefore, the purpose of this registry is to evaluate the safety and efficacy of Biofreedom stent in patients with coronary artery disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

LEADERS FREE II: BioFreedom™ Pivotal Study

NCT02843633

Acute Coronary Syndrome High Bleeding Risk

ACTIVE_NOT_RECRUITING NA

Leaders Free III: BioFreedom™ Clinical Trial

NCT03118895

Cardiac Death Myocardial Infarction Stent Thrombosis +2 more

COMPLETED NA

BioFreedom French Registry

NCT03745066

Coronary Artery Disease

UNKNOWN

BioFreedom US IDE Feasibility Trial

NCT02131142

Ischemic Heart Disease Stable Angina Unstable Angina +1 more

UNKNOWN PHASE2/PHASE3

BioFreedom™ BA9™ Ultra

NCT05331547

Cardiovascular Death Myocardial Infarction Revascularization

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Percutaneous coronary intervention (PCI) and related interventional cardiology field are rapidly growing in current era. First generation drug eluting stent (DES) needed long-term dual antiplatelet therapy (DAPT) for preventing future stent thrombosis. But, second generation DES showed better clinical outcomes in terms of target lesion revascularization and stent thrombosis. Later, polymer technology that was used to release drugs gradually improved. BASKET-PROVE II trial compared biodegradable polymer (BP) DES (Nobori, Terumo) with durable polymer DES (Xience Prime, Abbott Vascular) and bare metal stent (ProKinetik, Biotronik) for the safety and efficacy in 2-year follow-up. BP-DES showed 7.6% of event rates in composite endpoint including cardiac death, myocardial infarction (MI), clinically indicated target-vessel revascularization (TVR) which was non-inferior to DP-DES(6.8%) and superior to bare metal stent (12.7%). There were no statistical differences for the event rates of stent thrombosis, MI and cardiac death among three groups in 1-year follow-up. Biodegradable polymer has begun to emerge and suggested the possibility of shortening the duration of DAPT. LEEDERS-FREE trial was designed to confirm the safety and efficacy of polymer-free drug-coated stent (Biofreedom, Biosensors International Technologies, Singapore) compared to bare metal stent (Gazelle stent, Biosensors International Technologies, Singapore) in patients with high bleeding risk. During 390 days, drug coated stent showed significant superiority to bare metal stent for the safety composite endpoint (cardiac death, MI or stent thrombosis) (9.4% vs. 12.9%, P=0.0005). Clinically-driven target-lesion revascularization also showed significant differences between drug-coated stent (5.1%) and bare metal stent (9.8%) (P\<0.001). This results provided new therapeutic options that DAPT duration could be shortened to 1 month in patients with high bleeding risk. The rate of cardiovascular events was relatively higher than second generation DES. However, this result should be carefully interpreted because the main purpose of LEADERS-FREE trial is to enroll high bleeding risk patients who are generally excluded in second generation DES studies. Additional studies are needed because there are limited clinical evidences for extending these findings of LEADERS-FREE trial to generalized patients who are eligible to PCI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Aggravated Myocardial Ischemia Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

* Subject with ≥ 19 years
* Subject implanted with Biofreedom DCS within 1 month
* Subject who decided to participation and signed informed consent

Exclusion Criteria

* Known intolerance to heparin, aspirin, clopidogrel, biolimus, cobalt chromium or contrast media (Subject with hypersensitivity to contrast media controlled by steroid and pheniramine can be included this study, but subject with anaphylaxis to contrast media will be excluded).
* Pregnancy
* Woman who have a plan of pregnancy during study period
* Subject with life expectancy less than 12 months
* Subject with cardiogenic shock
* Subject treated with other drug-eluting stent (DES), bioresorbable vascular scaffold (BVS) or bare metal stent (BMS)
* Subject participating in other randomized controlled study with DES, BVS or BMS

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No